Role of the fractalkine receptor CX3CR1 polymorphisms V249I and T280M as risk factors for early‐onset coronary artery disease in patients with no classic risk factors

References

• Alexander R. W. Cytokine receptor CX3CR‐1 and fractalkine: New fractors in the atherosclerosis drama. Circ Res 2001; 89: 376–7
   PubMedGoogle Scholar
• Weber C., Schober A., Zernecke A. Chemokines, key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997–2008
   PubMed Web of Science ®Google Scholar
• Charo I. F., Taubman M. B. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858–66
   PubMed Web of Science ®Google Scholar
• Umehara H., Bloom E. T., Okazaki T., Nagano Y., Yoshie O., Imai T. Fractalkine in vascular biology: From basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34–40
   PubMed Web of Science ®Google Scholar
• Humphries S. E., Ridker P. M., Talmud P. J. Genetic testing for cardiovascular disease susceptibility: A useful clinical management tool or possible misinformation. Arterioscler Thromb Vasc Biol 2004; 24: 628–36
   PubMedGoogle Scholar
• Nassar B. A., Rockwood K., Kirkland S. A., Ransom T. P., Darvesh S., MacPherson K., et al. The effect of the multiple disease susceptibility genes APOE ε4, BChE–K variant, PPARγ2 Pro12 and ENOS T‐786C in early‐onset coronary artery disease. Clin Biochem 2006; 39: 109–14
   PubMedGoogle Scholar
• McDermott D. H., Halcox J. P. J., Schenke W. H., Waclawiw M. A., Merrell M. N., Epstein N., et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89: 401–7
   PubMed Web of Science ®Google Scholar
• McDermott D. H., Fong A. M., Yang Q., Sechler J. M., Cupples L. A., Merrell M. N., et al. Chemokine receptor mutant CX3CR1‐M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111: 1241–50
   PubMed Web of Science ®Google Scholar
• Niessner A., Marculescu R., Haschemi A., Endler G., Zorn G., Weyand C. M., et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. Thromb Haemost 2005; 93: 949–54
   PubMedGoogle Scholar
• Niessner A., Marculescu R., Kvakan H., Haschemi A., Endler G., Weyand C. M., et al. Fractalkine receptor polymorphisms V249I and T280M as genetics risk factors for restenosis. Thromb Haemost 2005; 94: 1251–6
   PubMedGoogle Scholar
• Lavergne E., Labreuche J., Daoudi M., Debre P., Cambien F., Deterre P., et al. on behalf of the GENIC investigators. Arterioscler Thromb Vasc Biol 2005; 25: 847–53
   PubMed Web of Science ®Google Scholar
• Gugl A., Renner W., Seinost G., Brodmann M., Pabst E., Wascher T. C., et al. Two polymorphisms in the fractalkine receptor CX3CR1 are not associated with peripheral arterial disease. Atherosclerosis 2003; 166: 339–43
   PubMed Web of Science ®Google Scholar
• Nassar B. A., Dunn J., Title L. M., O'Neill B. A., Kirkland S. A., Zayed E., et al. Relation of genetic polymorphisms of apolipoprotein E, angiotensin converting enzyme, apolipoprotein B‐100 and glycoprotein IIIa and early‐onset coronary heart disease. Clin Biochem 1999; 32: 275–82
   PubMedGoogle Scholar
• Genest J J. r., McNamara J. R., Ordovas J. M., Jenner J. L., Silberman S. R., Anderson K. M., et al. Lipoprotein cholesterol, apolipoprotein A‐I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792–802
   PubMedGoogle Scholar
• Dunder K., Lind L., Zethelius B., Berglund L., Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle‐aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). Am Heart J 2004; 148: 596–601
   PubMed Web of Science ®Google Scholar
• Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. INTERHEART study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case‐control study. Lancet 2004; 364: 937–52
   PubMed Web of Science ®Google Scholar
• Walldius G., Jungner I., Holme I., Aastveit A. H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A‐I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358: 2026–33
   PubMed Web of Science ®Google Scholar
• Miller S. A., Dykes D. D., Polesky H. F. A simple salting out method for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
   PubMed Web of Science ®Google Scholar
• P Armitage, M. A Berry. Blackwell Scientific Publications, London 1987, Statistical methods in medical research, 2nd edn
   Google Scholar
• Hansson G. K., Libby P. The immune response in atherosclerosis: A double‐edged sword. Nat Rev Immunol 2006; 6: 508–19
   PubMed Web of Science ®Google Scholar
• Ortlepp J. R., Vesper K., Mevissen V., Schmitz F., Janssens U., Franke A., et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med 2003; 81: 363–7
   PubMed Web of Science ®Google Scholar
• Moatti D., Faure S., Fumeron F., Amara Mel‐W, Seknadji P., McDermott D. H., et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 1925–8
   PubMed Web of Science ®Google Scholar
• Rios D. L. S., Callegari‐Jacques S. M., Hutz M. H. Endothelial nitric oxide synthase and fractalkine chemokine receptor polymorphisms on angiographically assessed coronary atherosclerosis. Clin Chem Acta 2005; 362: 138–46
   PubMedGoogle Scholar
• Apostolakis S., Baritaki S., Kochiadakis G. E., Igoumenidis N. E., Panutsopulos D., Spandidos D. A. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 2007; 119: 63–71
   PubMedGoogle Scholar
• Hattori H., Ito D., Tanahashi N., Murata M., Saito I., Watanabe K., et al. T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. Neurosci Lett 2005; 374: 132–5
   PubMed Web of Science ®Google Scholar
• Ghilardi G., Biondi M. L., Turri O., Guagnellini E., Scorza R. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: A genetic risk factor. Stroke 2004; 35: 1276–9
   PubMed Web of Science ®Google Scholar